<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04932187</url>
  </required_header>
  <id_info>
    <org_study_id>McCrest-3</org_study_id>
    <nct_id>NCT04932187</nct_id>
  </id_info>
  <brief_title>Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 3)</brief_title>
  <official_title>Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor (McCrest) Trial: Hepatobiliary, Pancreatic and Other Gastrointestinal Carcinoma (Non-stomach, Non-esophagi) (Cohort 3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center phase 1 trial to observe safety and efficacy of metronomic&#xD;
      capecitabine plus PD-L1 antibody camrelizumab to treat hepatobiliary, pancreatic and other&#xD;
      gastrointestinal carcinoma (non-stomach, non-esophagi) patients who had disease progression&#xD;
      after all standard regimens.&#xD;
&#xD;
      This study is one of the cohorts of a multi-cohort trial called Combination of Metronomic&#xD;
      capecitabine with Camrelizumab for treatment of refractory solid tumor (McCrest) trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatobiliary, pancreatic and other gastrointestinal carcinoma (non-stomach, non-esophagi)&#xD;
      patients who had disease progression after all standard regimens will be treated by&#xD;
      metronomic capecitabine plus camrelizumab. Metronomic capecitabine will be given as fixed&#xD;
      dose (500mg bid) orally. Camrelizumab will be given two-weekly (200mg once) intravenously.&#xD;
      This regimen will be administered until progression of disease, intolerable toxicity or&#xD;
      withdraw of consent.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of adverse events as assessed by CTCAE v5.0</measure>
    <time_frame>48 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hepatobiliary, Pancreatic and Other Gastrointestinal Carcinoma (Non-stomach, Non-esophagi)</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capecitabine 500mg bid. po. Camrelizumab 200mg ivgtt. d1 q2w</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine, Camrelizumab</intervention_name>
    <description>This is a single-arm study with all patients receiving these two drugs.</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male/female patients aged≥18 years.&#xD;
&#xD;
          2. Histologically confirmed hepatobiliary, pancreatic and other gastrointestinal&#xD;
             carcinoma (non-stomach, non-esophagi), without uncontrolled pleural effusion or&#xD;
             ascites.&#xD;
&#xD;
          3. Patients with advanced or metastatic disease who have disease progression after all&#xD;
             standard regimens, with measurable or unmeasurable lesions.&#xD;
&#xD;
          4. MSS or pMMR.&#xD;
&#xD;
          5. ECOG performance status 0 or 2, expected lifetime≥3 months.&#xD;
&#xD;
          6. Adequate organ function: Absolute neutrophil count (ANC) ≥1.5x109/L, White blood count&#xD;
             ≥3.5x109/L, Platelets ≥75x109/L, Hemoglobin (Hb) ≥70g/L, ALT/AST ≤2.5x ULN (for&#xD;
             patient with liver metastasis ALT/AST ≤5x ULN), Serum bilirubin ≤1.5x ULN, Serum&#xD;
             creatinine ≤1.5x ULN.&#xD;
&#xD;
          7. HBV infected patients (inactive/asymptomatic carrier, chronic or active) with HBV&#xD;
             DNA&lt;500IU/ml (or 2500 copies/ml).&#xD;
&#xD;
          8. Pregnancy test of female patients with fertile activity should be negative within 7&#xD;
             days before enrollment. Patients should keep contraception during treatment.&#xD;
&#xD;
          9. Willingness and ability to comply with the protocol for the duration of the study&#xD;
             including scheduled visits, examinations, investigations and treatment plans with&#xD;
             informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy or children bearing potential.&#xD;
&#xD;
          2. Brain or meningeal metastasis.&#xD;
&#xD;
          3. With second primary malignant diseases.&#xD;
&#xD;
          4. With uncontrolled auto-immune diseases, interstitial pneumonia, ulcerative colitis, or&#xD;
             patients who should receive long-term glucocorticoid treatment (&gt;10mg/d prednisone).&#xD;
&#xD;
          5. With uncontrollable complications&#xD;
&#xD;
          6. Inadequate organ function&#xD;
&#xD;
          7. Conditions which impact on pill taking (dysphagia, chronic diarrhea, bowel&#xD;
             obstruction).&#xD;
&#xD;
          8. known hypersensitivity reaction to any of the study drugs or components.&#xD;
&#xD;
          9. Other unsuitable conditions determined by investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Zhang, MD &amp; Ph. D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Min Shi, MD &amp; Ph. D</last_name>
    <phone>+86-21-64370045</phone>
    <email>sm11998@rjh.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Oncology, Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Zhang, MD &amp; Ph. D</last_name>
      <phone>+86-13818332497</phone>
      <email>junzhang10977@sjtu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Jun Zhang, MD &amp; Ph. D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 17, 2021</study_first_submitted>
  <study_first_submitted_qc>June 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2021</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Jun Zhang</investigator_full_name>
    <investigator_title>Chair of Department of Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

